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BACKGROUND: Poor reporting compromises the reliability and clinical value of prognostic tumour marker studies. We review articles
to assess the reporting of patients and events using REMARK guidelines, at the time of guideline publication.
METHODS: We sampled 50 prognostic tumour marker studies from higher impact cancer journals between 2006 and 2007.
The inclusion criteria were cancer; focus on single biological tumour marker; survival analysis; multivariable analysis; and not gene array
or proteomic data. Articles were assessed for the REMARK profile and other REMARK guideline items. We propose a reporting aid,
the REMARK profile, motivated by the CONSORT flowchart.
RESULTS: In 50 studies assessed for the REMARK profile, the number of eligible patients (56% of articles), excluded patients (54%)
and patients in analyses (98%) was reported. Only 50% of articles reported the number of outcome events. In multivariable
analyses, 54% and 30% of articles reported patient and event numbers for all variables. Of the studies, 66% used archival
samples, indicating a potentially biased patient selection. Only 36% of studies reported clearly defined outcomes.
CONCLUSIONS: Good reporting is critical for the interpretability and clinical applicability of prognostic studies. Current reporting
of key information, such as the number of outcome events in all patients and subgroups, is poor. Use of the REMARK profile
would greatly improve reporting and enhance prognostic research.
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Every year, thousands of articles are published on prognostic
tumour markers, often with contradictory results for the same
marker and disease. Many studies are so poorly reported that
they lack the key information that readers need to evaluate
their reliability and clinical applicability. It is of concern that
health-care professionals may direct patient treatment on the
basis of poorly reported studies. Systematic reviews of prognos-
tic markers are often unable to include data from the majority
of studies because of poor reporting (Riley et al, 2003, 2009;
Malats et al, 2005; de Azambuja et al, 2007).
REMARK reporting guidelines (Table 1) were developed to
encourage transparent and complete reporting in prognostic
studies evaluating a single tumour marker on the basis of a
recommendation from the National Cancer Institute and European
Organisation for Research and Treatment of Cancer (McShane
et al, 2005b). Reporting guidelines, such as the CONSORT
guidelines for reporting randomised controlled trials (RCTs)
(Moher et al, 2001), are important tools used by authors, journal
editors and peer reviewers.
The variability in methods and conflicting results seen across
prognostic studies makes reporting of key study details critical
(Riley et al, 2003; Malats et al, 2005; Sauerbrei, 2005). Variability of
study results can be partly attributed to patient spectrum/
treatment, specimen characteristics, assay methods, study design
and statistical analysis. The REMARK guidelines make specific
reporting recommendations for each of these areas.
In addition, variation in prognostic studies is also caused by
underpowered studies (Bentzen, 2001), multiplicity in analysis
(Faraggi and Kramar, 2000), different cut points for markers
(Sauerbrei, 2005), missing data (Burton and Altman, 2004),
selective outcome reporting (Kyzas et al, 2005b) and publication
bias (Kyzas et al, 2007a). These aspects of study design and
statistical analysis might not be improved by better reporting, but
might be more easily identified.
Systematic reviews in breast cancer (Altman, 2007), neuro-
blastoma (Riley et al, 2003), prostate cancer (Sutcliffe et al, 2009)
and bladder cancer (Malats et al, 2005) found that poor reporting
was common and limited the clinical applicability of studies.
Often, only a minority of studies report sufficient information that
can be considered for inclusion in a meta-analysis. In a systematic
review of neuroblastoma, only 57 of 575 prognostic studies
reported estimates for the hazard ratio or loge(hazard ratio)
(Riley et al, 2003). Kyzas et al (2005a) found that evidence of
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editorial, McShane et al (2005a) discussed the process of identi-
fying clinically useful cancer prognostic markers and stressed that
‘more complete and transparent reporting of marker studies would
make it easier to distinguish carefully designed and analysed
studies from haphazardly designed and over-analysed studies’.
Poor reporting of patient flow in studies and difficulties in
getting an overview of all analyses performed have led to the
development of a REMARK profile, inspired by the CONSORT flow
diagram (Moher et al, 2001), to summarise key information on
patient flow, study characteristics and statistical analyses. Table 2
shows a REMARK profile for an illustrative example. The
REMARK profile will be published as a part of the forthcoming
REMARK guideline explanatory document (personal communica-
tion REMARK guidelines group). The flow of patients through
various analyses can be complicated in prognostic studies,
particularly when there are missing data, multiple analyses or
subgroup analyses. It is often difficult to identify all analyses.
Results of several subgroup analyses are sometimes mentioned
only very briefly, if at all.
In this article, we have conducted a review of the reporting of
items from the REMARK guidelines in prognostic studies of
tumour markers published in higher impact journals from January
2006 to April 2007. As the earliest publication of the REMARK
guidelines was in August 2005, it was very unlikely that the
guidelines were known to the authors when submitting the first
version of their papers. Indeed, none of the papers referen-
ced REMARK. Therefore, our study summarises the reporting
of prognostic marker studies in the pre-REMARK era. In a
following study, we intend to assess publications from 2009 using
identical criteria. We assessed the REMARK reporting guideline
items for patient characteristics, study design, data analysis and
presentation of results, including the items in the REMARK profile.
MATERIALS AND METHODS
Literature search
A systematic hand search of five higher impact cancer journals
(Cancer, Cancer Research, International Journal of Cancer, Journal
of Clinical Oncology) that publish relevant articles was completed
for 2006, and that for Clinical Cancer Research continued up to
April 2007. The first 10 eligible articles for each journal were
selected. We also planned to include the European Journal of
Cancer, but found only four articles in 2006 that met our inclusion
criteria and therefore we substituted Cancer Research instead.
Inclusion criteria
Articles were included if they examined the impact of a prognostic
biological marker on at least one of overall survival (OS), disease-
free survival (DFS), disease-free progression or recurrence in
cancer patients, focused on one prognostic marker, but performed
multivariable analysis with one or more additional variables.
Because of very different design and analysis issues, microarray,
gene profiling and proteomics articles were excluded. The
REMARK guidelines were developed for prognostic studies that
evaluate a single tumour marker and are not designed for these
study designs.
Biological markers included, for example, laboratory measure-
ments, immunohistochemistry and DNA/RNA measurements, but
did not include variables such as weight, BMI, angiogenesis
measured by ultrasound or clinical tests such as reflex and lymph
drainage pattern by scan.
Prognostic studies evaluating a single tumour marker were
included irrespective of whether patients’ data were from planned
prospective trials, from clinical registries or other sources. We also
did not have any limitation on the sample size of the study.
Table 1 Reporting recommendations for tumour marker prognostic
studies (REMARK)
INTRODUCTION
1. State the marker examined, the study objectives, and any pre-specified
hypotheses.
MATERIALS AND METHODS
Patients
2.
a Describe the characteristics (e.g., disease stage or comorbidities) of the
study patients, including their source and inclusion and exclusion criteria.
3.
a Describe treatments received and how chosen (e.g., randomised or rule-
based).
Specimen characteristics
4. Describe type of biological material used (including control samples) and
methods of preservation and storage.
Assay methods
5. Specify the assay method used and provide (or reference) a detailed
protocol, including specific reagents or kits used, quality control
procedures, reproducibility assessments, quantitation methods, and
scoring and reporting protocols. Specify whether and how assays were
performed blinded to the study end point.
Study design
6.
a State the method of case selection, including whether prospective or
retrospective and whether stratification or matching (e.g., by stage of
disease or age) was used. Specify the time period from which cases were
taken, the end of the follow-up period, and the median follow-up time.
7.
a Precisely define all clinical end points examined.
8.
a List all candidate variables initially examined or considered for inclusion in
models.
9. Give rationale for sample size; if the study was designed to detect a
specified effect size, give the target power and effect size.
Statistical analysis methods
10.
a Specify all statistical methods, including details of any variable selection
procedures and other model-building issues, how model assumptions
were verified, and how missing data were handled.
11. Clarify how marker values were handled in the analyses; if relevant,
describe methods used for cut point determination.
RESULTS
Data
12.
a Describe the flow of patients through the study, including the number of
patients included in each stage of the analysis (a diagram may be helpful)
and reasons for dropout. Specifically, both overall and for each subgroup
extensively examined report the number of patients and the number of
events.
13. Report distributions of basic demographic characteristics (at least age
and sex), standard (disease-specific) prognostic variables, and tumour
marker, including numbers of missing values.
Analysis and presentation
14.
a Show the relation of the marker to standard prognostic variables.
15.
a Present univariate analyses showing the relation between the marker and
outcome, with the estimated effect (e.g., hazard ratio and survival
probability). Preferably provide similar analyses for all other variables
being analysed. For the effect of a tumour marker on a time-to-event
outcome, a Kaplan–Meier plot is recommended.
16.
a For key multivariable analyses, report estimated effects (e.g., hazard ratio)
with confidence intervals for the marker and, at least for the final model,
all other variables in the model.
17.
a Among reported results, provide estimated effects with confidence
intervals from an analysis in which the marker and standard prognostic
variables are included, regardless of their statistical significance.
18. If done, report results of further investigations, such as checking
assumptions, sensitivity analyses and internal validation.
DISCUSSION
19. Interpret the results in the context of the pre-specified hypotheses and
other relevant studies; include a discussion of limitations of the study.
20. Discuss implications for future research and clinical value.
aItems assessed in this study. (produced permission of authors of McShane LM,
Altman DG, Sauerbrei W et al. from Br J Cancer 2005; 93: 387–391).
REMARK profile for reporting prognostic tumour marker studies
S Mallett et al
174
British Journal of Cancer (2010) 102(1), 173–180 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sOne reader (SM) selected articles for inclusion. Queries on
article inclusions were referred to second readers (AT, WS, DA).
Validity assessment and data abstraction
We assessed 50 articles in random order using a pre-piloted
data extraction form of 52 items based on the REMARK guidelines
(McShane et al, 2005b) covering study, patient and article
characteristics; definition of study outcomes; and univariable
and multivariable analyses. The form is available on request. Two
reviewers (SM and AT) completed duplicate data extraction
from 15 articles (two articles were subsequently excluded as the
journal was excluded) with reference to a third reader where
necessary. Differences were mostly due to difficulty in locating
information in articles or use of form. Modifications to the data
extraction form improved reliability. Agreement between readers
was 89% for the last five articles, with disagreements due to
difficulties in finding information or ambiguity in articles. As
pre-specified for high agreement, a single reader (SM) completed
the remaining articles, referring queries to another reader.
Reporting of treatment was problematic and two readers
reviewed the text from all articles.
Items in the REMARK profile were assessed for one outcome
per article. Table 2 provides a suggested reporting format for
the REMARK profile, with the REMARK profile items illustrated
using data from an example article (Pfisterer et al, 1994). If there
was more than one disease or multivariable outcome in the article,
the first reported in the title, abstract or text was selected. Within
each article, the same outcome was assessed for univariable and
multivariable analyses.
Overview of reporting the number of patients and events
A score was developed to allow a visual representation of reporting
eight key items per article from the REMARK profile (Table 3).
This score was used solely for descriptive purposes in this study,
recognising the fact that not all information has equal importance.
Table 2 REMARK profile of patients, variables and statistical analyses (Study profile for Pfisterer et al, 1994). The REMARK profile is shown for illustrative
purposes in an adaptable format. Additional rows can be included for each multivariable analysis, subgroup analysis or further outcome investigated
(a) Patients, treatment and variables
Study and marker Remarks
Marker (If non-binary: how was marker analysed? continuous or
categorical. If categorical, how are cutpoints determined?)
M¼ploidy (diploid, aneuploid)
Further variables (variables collected, variables available for
analysis, baseline variables, patient and tumour variables)
v1¼age, v2¼histological type, v3¼grade, v4¼residual tumour,
v5¼stage, v6¼ascites
a,v 7¼oestrogen
a,v 8¼progesterone
a,
v9¼CA-125
a
Patients n Remarks
Assessed for eligibility 257 Disease: advanced ovarian cancer, stage III and IV
Patient source: Surgery 1982–1990, University Medical
Center Freiburg
Sample source: archived specimens available
Excluded 73 General exclusion criteria
b, non-standard therapy
b,C V4 7%
b
Included 184 Previously untreated.
Treatment: all had platinum-based chemotherapy after surgery
With outcome events 139 Overall survival: death from any cause
(b) Statistical analyses of survival outcomes
Analysis Patients Events Variables considered Results/remarks
A1: Univariable (Provide for all variables. Give numbers as range
if variables have different numbers of missing values)
184 139 M,v1 to v5 Tab 2, Fig1
A2: Multivariable 174 133 M,v1,v3 to v5 Tab 3 (v2 omitted because of many
missing data; backward selection, see text)
A3: Effect for ploidy adjusted for v4 184 139 M, 4 Fig 2 (based on the result of A2)
A4: Interaction ploidy and stage 175 133 M, v1, v2, v4, v5 See text
A5: Ploidy in stage subgroups
v5¼III 128 88 M Fig 3
v5¼IV 56 51 M Fig 4
aNot considered for survival outcome as these factors are not considered as ‘standard’ factors and/or number of missing values are relatively large.
bValues not given in the paper.
Table 3 Reporting of patient and event numbers
REMARK profile item Number of articles reporting % (n¼50)
Number of patients overall
Assessed for eligibility 56 (28)
Excluded 54 (27)
Number available for analysis
Patients 98 (49)
Events 50 (25)
Numbers in univariable analysis
a
Patients 54 (27)
Events 21 (11)
Numbers in multivariable analysis
b
Patients 54 (27)
Events 30 (15)
Median number of items reported
c 4
aOnly one univariable outcome per article, but univariable analyses for all variables are
assessed for this outcome. Univariable outcome is same as outcome used as for
multivariable analysis.
bOnly one multivariable analysis assessed.
cMedian of these
eight items.
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reported, and zero if unclear or not reported. Only one outcome
was assessed per article for univariable and multivariable analyses
for simplicity of presentation. An analysis based on multiple
outcomes per article did not materially change the results.
Data were plotted in Stata 10.0 (StataCorp, College Station,
TX, USA).
RESULTS
Figure 1 shows a flow diagram of included articles. A full list is
presented in a Supplementary Table. The cancer sites included are
breast (10 articles); colorectal (6); urological (6); skin (6); ovary
(5); head and neck (5); brain and nervous system (4); upper GI and
pancreas (4); haematological malignancies (2); endometrium (1);
and bone and soft tissue (1).
A total of 44 different primary prognostic markers were
investigated in 50 articles, with six markers each studied in two
articles. Of these six markers, four were presented for different
cancer sites and two for the same site; one marker was reported in
two articles by the same authors at the same site. Of the articles,
54% (27) used immunohistochemistry to identify the primary
marker, 22% (11) used PCR, 12% (6) used ELISA, 4%(2) used
microscopic scoring but not immunohistochemistry and 6% (3)
used other methods. In one article, the method was unclear.
Tables 3, 4 and 5 show the findings across the areas assessed.
Reporting of patients and events
The numbers of patients and events are key items in the REMARK
profile that provide an overview of patient flow in a study.
The number of events in analyses is the ‘effective’ sample size
and dictates the variability of study estimates.
We assessed key items from the REMARK profile that relate
to the number of patients and events based on a single outcome
per article (Table 3). Only 50% (25) of articles reported the number
of events included in analyses, with no difference observed
between OS and DFS outcomes. The number of excluded patients
was reported in seven studies, could be calculated in 20 studies,
but was unavailable in 23 studies because of a lack of reporting of
eligible patients (22) or included patients (1). In 22 of 27 studies
for which data were available, the number of patients included in
analyses was fewer than the number of eligible patients.
If data are missing, a full reporting of univariable analysis
with survival outcomes requires both patient and event numbers
for all variables analysed, not just the biomarker of interest.
Analyses should indicate the amount of missing data for
covariates.
We assessed the reporting of patient and event numbers for
all variables in univariable analyses. For the primary study marker,
98% (49) of articles reported patient numbers and 42% (21)
reported event numbers. Only 56% of articles reported the
explicit univariable analysis of variables other than the primary
marker. For all articles, regardless of their explicit reporting of
the univariable analysis of all variables, 55% (27) of articles repor-
ted patient numbers for variables available for univariable analyses
but only 11 reported event numbers (Table 3).
For multivariable analyses, 54% (27) and 30% (15) of articles
reported patient and event numbers, respectively, including
12 studies without missing data in which all patients available
for analysis were included in the multivariable analysis so that
numbers could be inferred even if not specifically reported for
the multivariable analysis.
Figure 2 shows a graphical overview of the items reported per
article, using star plots. Each article is represented by a star,
with the eight spokes corresponding to the patient and event items
from Table 3. Only articles 1–7 reported all eight items. Articles
reporting fewer items on patient and event numbers from the
REMARK profile tended to report patient numbers rather than
event numbers. Overall, half (50%) of all articles did not provide
event numbers for any reported outcomes (spokes at 8, 9, and
10 o’clock).
Five high profile cancer journals 2006/2007
￿  Search for first 10 articles from each journal
￿  One journal substituted as it only four eligible articles in 2006
￿ Article citations (n=3168 in five journals)
Rejected on title (n=2967)
Excluded references (n=151)
￿ Not prognosis (n=8)
￿ Not human (n=27)
￿ Not survival (n=50)
￿ Not biological marker (n=5)
￿ Not single factor (n=42)
￿ Not multivariable (n=11)
￿ Other (n=8)
Abstracts or full article read for inclusion criteria (n=201)
Data extraction (n=50)
￿  Duplicate data extraction on 13 articles
Figure 1 Flowchart of included articles.
Table 4 Patient, study and outcome reporting (n¼50)
Topic Items reported % (n) articles
Patients Source of patients (clinical setting/clinical trial) 82 (41)
Age
a 60 (30)
Stage or grade of patients 92 (46)
Selection of patients?
Apparently unselected 8 (4)
Selected, some criteria given 56 (28)
Unclear 36 (18)
Study Start date of patient recruitment
b 74 (37)
Finish date of patient recruitment 74 (37)
End of follow-up date? 18 (9)
Median follow-up for patients 58 (29)
Completeness of followup 26 (13)
Outcome Outcomes examined
OS and DFS 46 (23)
OS only 46 (23)
DFS only 8 (4)
Definition of multivariable outcomes
Multivariable outcome clearly defined
c 36 (18)
OS (n¼29)
Explicitly any death 2 (1)
Cancer death only 20 (10)
Type of death unclear 36 (18)
DFS (n¼19)
DFS including deaths
c 14 (7)
DFS not including deaths 0 (0)
DFS but unclear if includes deaths 24 (12)
Multivariable outcome unclear 6 (3)
aMean, or median age plus age range.
bTen articles reported dates spanning more
than 10 years.
cOne multivariable outcome assessed per article. This includes two
articles that did not define type of death for DFS.
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REMARK items 2, 3 and 6 recommend reporting of patient
characteristics, treatments received and methods of patient
selection. These are key to understanding the transferability and
applicability of study results and the potential for study bias
(Hayden et al, 2006).
The source of patients was reported in 82% (41) of articles
(Table 4). Key patient characteristics in prognostic cancer research
usually include age and disease severity (stage or grade of cancer).
We defined clear reporting of age as including mean or median
age plus age range, reported in only 60% (30) of articles. Of the
articles, 92% (46) reported disease severity.
Heterogeneity in diagnosis and treatment of patients is common
within prognostic studies because of the use of existing clinical
patient databases (Pfisterer et al, 1994; Gasparini, 1998; Sauerbrei,
2005). We attempted to assess the reporting of patient treat-
ment (item 3, Table 1). Most papers provided some information,
but it was difficult to assess what constituted good reporting
because of multiple treatments, different treatment time points
relative to surgery, our lack of specialist knowledge of different
cancers and the level of detail reported. We were unable to define a
robust way to formally assess the reporting of treatment and how
it was determined, across this range of cancer sites. Examples of
details included treatments offered under local or national
recommendations, but often not treatment uptake. When details
were given, it was often not possible to judge how many patients
received treatment, as seen in the following example ‘The tumours
were radically resected if possible and most patients with high-
grade gliomas also received radiotherapy.’ (Haapasalo et al, 2006).
In all, 32% (16) of articles included treatment as a variable in
univariable or multivariable analyses, or as stratification in the
multivariable model.
Selection of patients from clinical populations was explicitly
reported in 56% (28) of articles, with some selection criteria
reported. In 36% (18) of articles, it was unclear whether patients
were selected, as no criteria were reported; however, often selection
was indicated implicitly as archival tumour bank samples were
used. In 8% (4) of articles, patients were apparently unselected
other than by time, as patients were enrolled from prospective
trials with no reported exclusions (two studies), were consecutive
patients (one study) or all of the consented patients (one study).
The most frequently cited explicit or implicit selection criteria
were availability of patient samples (43 articles), covariate data
(12), clinical follow-up (7), disease/disease stage (5), treatment (3),
level of primary marker (3) and comorbidity (2). Articles often
cited several selection criteria. In 66% (33) of articles, samples
were from an archive, whereas in 34% (17), samples were
apparently collected for the specific study, including five articles
in which samples were from phase II trials or RCTs.
Reporting of study characteristics
Item 6 of the REMARK guidelines recommends reporting
key study dates. Clinical interpretation of a study depends on its
time frame. Of the articles, 74% (37) reported both the start and
Table 5 Analysis methods and estimates (n¼50 articles)
Topic Items reported
%( n)
articles
Analysis
method
Cox only 96 (48)
Cox and logistic regression 2 (1)
Not reported 2 (1)
Assumptions of proportional hazards examined? 8 (4)
Is the relationship of the primary marker with the
standard prognostic variables shown?
a
80 (40)
Univariable
analysis
Primary marker
Effect estimate (e.g. HR)
b 58 (29)
CI for effect estimate 42 (21)
P-value for the marker 96 (48)
KM graph by the primary marker 98 (49)
Other variables
Explicit other univariable analyses 56 (28)
Effect estimates for markers (e.g. HR)
b 38 (19)
CI for effect estimates 24 (12)
Multivariable
analysis
More than one multivariable analysis reported 60 (30)
Effect estimate for primary marker 84 (42)
Effect estimate for other variables in the final model
All 66 (33)
Some 10 (5)
CI for effect estimates
c 84 (42)
P-value for marker
All variables 72 (36)
Some variables 22 (11)
KM graph for adjusted effect of the marker 0 (0)
aYes if age, stage or grade is considered.
b10 articles reported % 5-year OS or DFS as
effect estimate.
cThis includes six articles that reported 95% CI for only one variable
and five that reported for the primary marker only.
Key
Patients eligible for study
Patients excluded
Patients in analyses
Patients in univariable analyses
Patients in multivariable analyses
Events in analyses
Events in univariable analyses
Events in multivariable analyses
1 2 3 4 5 6 7 8
9 10 11 12 13 14 15 16
17 18 19 20 21 22 23 24
25 26 27 28 29 30 31 32
33 34 35 36 37 38 39 40
41 42 43 44 45 46 47 48
49 50
Figure 2 Reporting of patient and event numbers. Each article is
represented by a star, with the eight spokes corresponding to the patient
and event items detailed in the key below and in Table 1. Spokes are
ordered in such a manner that reporting of patient event numbers is
displayed at 8, 9 and 10 o’clock. Articles are ordered by the total number of
items reported.
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date was reported in only 18% (9) of studies (Table 4).
Loss to follow-up and completeness of study data are impor-
tant aspects to assess the potential for study attrition bias
(Schemper and Smith, 1996; Clark et al, 2002). Median follow-up
was reported in 58% (29) studies, with a statement pertaining to
completeness of follow-up in only 26% (13) studies.
Study outcomes and their definition
Item 7 of REMARK specifies the explicit definition of clinical
end points, which is required for the interpretation of study results
(Altman et al, 1995). With OS, it should be clear whether events
refer to all deaths or only cancer deaths. For DFS, disease response
or disease progression events need precise definition, as well
as whether deaths are included as events, and which type of death.
Of the articles, 92% (46) examined OS; in half of them (23), this
was the only outcome examined (Table 4). A total of 54% (27) of
articles examined DFS, most of which (23) also included OS.
We assessed the definition of the outcome measure used in the
first multivariable analysis in each article (see Materials and
methods). Only 36% (18) of studies provided a clear definition of
the outcome (Table 4). In articles using DFS as an outcome, seven
articles included death as an event, but two of these did
not clarify whether this event consists of all deaths that occurred
or cancer deaths only.
Study variables
Item 8 of REMARK requires a list of all candidate variables initially
examined or considered for inclusion in models. Over-optimistic
models can result from multiplicity when significance testing is
used on a large number of candidate variables, particularly with
the small study sizes found in this sample (Altman, 2006).
The median number of variables investigated in the multi-
variable model was 8 (IQR 6–8, range 3–19). In eight studies, the
number of variables was unclear; hence, we used the number of
variables reported in tables, which is likely to be an underestimate.
A total of 72% (36) of studies included age and 98% (49) included
disease severity as study variables.
Size of studies
We extracted the size of studies in our sample of 50 papers. Of
the articles, 98% (49) reported the overall number of patients,
therefore our estimate of median size is reliable. However, only
50% (25) of articles reported the number of events for any
outcome, therefore these estimates could be subject to reporting
bias. We speculate that the number of events is smaller in articles
not providing these numbers.
The median number of patients per study was 136 (IQR 77–234)
range 43–889. The median number of events for OS was 72 (IQR
31–116, range 6–312, n¼23 out of 46). The median number of
events for DFS was 38 (IQR 23–71, range 17–280, n¼11 out of 27).
Estimates of effect size and uncertainty
Items 15, 16 and 17 of REMARK (McShane et al, 2005b)
recommend the reporting of estimated effects (e.g., hazard ratio
and survival probability) with confidence intervals for all variables
in univariable and multivariable analyses. This facilitates the
inclusion of study results in systematic reviews. A Kaplan–Meier
plot is recommended to present the association of a marker with
time-to-event outcomes.
Estimates of the effect size for the primary marker were reported
for univariable analyses in 58% (29) of articles, 42% with
confidence intervals, whereas 96% reported P-values only (Table 5).
In all, 98% (49) of articles presented Kaplan–Meier plots for the
primary marker. Effect estimates and confidence intervals for
variables other than the primary marker were reported less
frequently.
In the multivariable analysis, effect estimates were more
frequently reported, in 84 and 66% of studies for the primary
marker and all markers, respectively.
Analysis methods
Item 10 (McShane et al, 2005b) includes recommendations to
report statistical model methods and testing of assumptions. Item
14 requests the reporting of the relation of the marker to standard
prognostic variables.
A total of 98% (49) of articles used the Cox proportional hazards
method (Table 5). In all, 8% (4) of articles reported testing the
assumption of proportional hazards and 80% of studies reported
the relationship of the primary marker to at least one of age, stage
or grade.
Examples of better reporting
We highlight three examples of better reporting, in which between
23 and 28 items of 39 items extracted in our study assessment were
reported from the REMARK profile and from the items detailed in
Tables 4 and 5 (Huang et al, 2006; Wadehra et al, 2006; Wang et al,
2006), with the proviso that in these studies outcome definitions
are not explicitly described.
DISCUSSION
This study provides evidence of poor reporting in the current
prognostic literature, and supports the potential value of using the
REMARK checklist and REMARK profile to improve reporting.
Poor reporting is a major obstacle to the applicability, transpar-
ency and evidence-based clinical use of current prognostic marker
studies to direct patient treatment (Sauerbrei, 2005; Riley et al,
2006; Sauerbrei et al, 2006).
The REMARK guidelines were developed to improve reporting
in prognostic studies of tumour markers by clearly indicating those
events that are considered to be relevant and important enough to
be reported so that poor reporting can be easily identified by non-
specialist journal editors, peer reviewers, readers and authors.
REMARK profile
Our review assesses the reporting of items of the REMARK profile,
a rapid overview of patients and events in a prognostic study
designed to accompany the REMARK guidelines, similar to the
CONSORT flowchart for RCTs. In addition, it gives an overview
of the multiplicity of analyses conducted in each study. Table 2
shows an illustrative example from a study by Pfisterer et al (1994)
in an adaptable format. Additional rows can be included for each
multivariable analysis, subgroup analysis or for further outcomes
investigated.
This research is new, as the REMARK profile assesses an
overall picture of patients and events reported across studies as
a whole. We found that a typical article only reported half of
the REMARK profile items and these were often difficult to find.
Half of the articles (25 out of 50) did not report the number
of events for any analyses or outcomes. Studies in our sample had
low sample sizes, with a median of 72 (IQR 31–116) events for OS
and 38 (IQR 23–71) for DFS outcomes. Articles included a median
of 136 patients (IQR 77–234).
Previous research has assessed parts of the REMARK profile,
but has not addressed the flow of patients in a prognostic study as
a whole. A review of prognostic studies on liver cirrhosis found
that excluded patients were reported in one of 13 studies (Infante-
Rivard et al, 1989). A review of survival analyses found that 93% of
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papers gave the number of events for each outcome (Altman et al,
1995). Studies of p53 were found to have a mean size of 86 patients,
with 70% of studies enrolling 100 or fewer patients (Malats et al,
2005). Similarly, 83% of TP53 studies were of fewer than 100
patients (Kyzas et al, 2005b). Typically, prognostic studies are
too small to be reliable, either to detect important prognostic
factors or to provide substantial evidence for factors identified
(Altman and Lyman, 1998; Faraggi and Kramar, 2000; Bentzen,
2001; Altman and Riley, 2005; Sauerbrei et al, 2006).
The source of patients was reported in 82% of articles, with 92%
of articles indicating selection of patients from those populations.
Of the studies in our sample, 66% indicated selection due to
availability of patient specimens from hospital archives. Similarly,
specimen or test availability was reported as selection in inclusion
criteria in 40% of articles (Burton and Altman, 2004) Selection bias
is common when archival tumour samples are used, as sample
collection is a part of diagnosis and treatment, and is guided by
disease severity (Hoppin et al, 2002). Determinants of selection
and their implications for generalisability and interpretation of
prognostic findings need to be reported.
Other REMARK items
Our study included several items from REMARK guidelines
that are not in the REMARK profile. These have been investigated
in previous research in other areas of prognosis, including
systematic reviews of individual diseases or tumour markers,
and have also found evidence or discuss poor reporting of follow-
up time (Marx and Marx, 1997; Malats et al, 2005; Altman, 2007);
loss of follow-up (Infante-Rivard et al, 1989; Burton and Altman,
2004; Altman, 2007); study dates (Altman, 2007); effect estimates
and confidence intervals for univariable and multivariable analyses
(Riley et al, 2003; Scholten-Peeters et al, 2003; Barth et al, 2004;
Kuijpers et al, 2004; Malats et al, 2005); definitions of outcomes of
overall survival and disease-free survival (Altman et al, 1995;
Malats et al, 2005; Hudis et al, 2007; Kyzas et al, 2007b); and
heterogeneity of patient and patient treatments (Pfisterer et al,
1994; Gasparini, 1998; Sauerbrei, 2005).
We assessed the reporting of items in the REMARK guidelines
for prognostic studies with a focus on a single tumour marker.
A complementary study from Kyzas et al (2007b) assessed
reporting on the study design and assay methods of the REMARK
guidelines. Similar findings of poor reporting has been found in
other prognostic articles and other medical areas (Scholten-Peeters
et al, 2003; Barth et al, 2004; Kuijpers et al, 2004). We studied
higher impact articles, but poor reporting has been found across
other journals and study types (Altman, 2007; Kyzas et al, 2007b).
Previous to the widespread availability of journal webspace for
additional information, it could have been argued that some
aspects of poor reporting were necessitated by word restrictions.
However, key items such as number of events would require only a
few words. The reliability of our assessment was good, as we used
duplicate data extraction until data extraction had a high level of
agreement between two independent readers.
Good reporting cannot make up for poor study design;
however, it can facilitate the identification of poor studies.
There is plenty of evidence that poor study design and analysis
are widespread in prognostic studies (Altman and Lyman, 1998;
Altman and Riley, 2005; Sauerbrei, 2005). In addition, serious
concerns about the high level of reporting bias has been raised
(Kyzas et al, 2007a).
We found 44 different prognostic markers in 50 articles.
Despite the limited number of prognostic factors used in standard
clinical practice, the prognostic literature is replete with progno-
stic markers. Systematic reviews even within single diseases,
neuroblastoma and non-small lung cancer, have identified 130 and
169 different prognostic markers, respectively (Brundage et al,
2002; Riley et al, 2003).
Assessing 10 articles in each of five journals does not allow a
reliable comparison between the reporting quality of journals.
There was some variation in reporting between the five journals,
but more important is that all journals published articles with wide
variations in the quality of reporting.
The wide variation and poor quality of reporting within these
and other journal articles suggest that adherence to the REMARK
guidelines would produce a framework to facilitate author, peer
reviewer and editor consistency. We note that many journals,
including three journals assessed in this study (Cancer, Cancer
Research and International Journal of Cancer), do not mention or
ask for adherence to REMARK guidelines for tumour marker
studies in their instructions to authors (checked 6 October 2009).
As the REMARK guidelines were first published in June 2005,
our study summarises the reporting of prognostic marker studies
in the pre-REMARK era. In a following study, we intend to assess
publications from 2009 using identical criteria.
In conclusion, we assessed the reporting of elements of
the REMARK guidelines that relate to patients and events in
published reports of tumour marker prognostic studies. Recently,
the REMARK guidelines have been used in a systematic review
of prognostic studies in stroke (Whiteley et al, 2009). Poor repor-
ting of patient and event numbers had been anticipated, but we
were dismayed that less than half of the articles reported
event numbers, so readers had no information on an effective
study sample size. We emphasise the importance of the REMARK
profile as a standardised format for presenting key details of a
tumour marker prognostic study. We hope that if journals
required authors to include a REMARK study profile, those
articles would have enhanced transparency and value for clinicians
and patients.
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